CPA
AGIO icon

Capital Performance Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Capital Performance Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-155
Closed -$6.89K – 231
2024
Q3 		$6.89K Buy
+155
New +$7.04K ﹤0.01% 975

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Capital Performance Advisors's AGIO Position: Q4 2024 in Review

Capital Performance Advisors sold out of Agios Pharmaceuticals (AGIO) in Q4 2024, closing a stake of 155 shares — an estimated $6.89K sold.

Capital Performance Advisors first reported a position in AGIO in Q3 2024 and held it in 1 quarter. The position peaked at $6.89K in Q3 2024. 224 funds tracked by Wall St. Rank hold AGIO as of Q4 2024.

  • Capital Performance Advisors reported no remaining Agios Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 155 Agios Pharmaceuticals shares in Q4 2024, an estimated $6.89K.
  • Capital Performance Advisors first reported a position in Agios Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Agios Pharmaceuticals position peaked at $6.89K in Q3 2024.
  • 224 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.